23me-00610
23andme
['23me-00610']
23andme announces phase 1 results from the first-in-human phase 1/2a study of 23me-00610, an investigational antibody targeting cd200r1 - clinical results to be presented at the aacr annual meeting 2023 showed 23me-00610 demonstrated an acceptable safet... 
CEO Of Digital Media Online